(BPT) – Do you live with persistent, moderate-to-severe asthma, COPD, allergies, eczema or hives? Inflammation is often a major factor in the severity of your symptoms. It could also be a factor if ...
Reynold A. Panettieri Jr., MD, examines the application of biologic therapies in the treatment of respiratory conditions. Biologics are currently available for asthma management and being studied in ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In those with and those without emphysema, patients ...
Panelists discuss how identifying type 2 inflammation in patients influences treatment decisions by steering clinicians toward targeted therapies, such as biologics or other immunomodulators, that ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The phase 3 BOREAS trial included adults with ...
24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma COPD ...
Announcing a new article publication for Cardiovascular Innovations and Applications journal. Asthma and cardiovascular diseases (CVDs) are intricately linked, because of their widespread prevalence ...
Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...
Two weeks of an intensive diabetes treatment has shown promise in improving periodontal disease inflammation among patients with type 2 diabetes. The corresponding study was published in Diabetes, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results